McArthur Grant A GA

Previous page
1 / 2
You're on page 1
page 2
Next page

Sort by:

Relevance

Page size

Expression data from BRAFV600E A375 melanoma cells treated with vehicle or vemurafenib

Vemurafenib is a BRAF inhibitor with specificity for the most common BRAF mutant encountered in melanomas (BRAFV600E). Vemurafenib suppresses the proliferation of BRAF mutant human melanoma cells by suppressing downstream activation of the MEK/ERK mitogen activated protein kinases. We used microarra...

ORGANISM(S): Homo sapiens

2014-05-20 | E-GEOD-42872 | biostudies-arrayexpress

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

Not available

S-EPMC4878037 | biostudies-literature

Expression data from BRAF-mutant melanoma cell lines

Melanoma cell lines were assessed for differences in gene expression patterns between the lines sensitive and resistant to BRAF and MEK inhibitor drugs. 22 BRAF-mutant melanoma cell lines were assessed for response to BRAF and MEK inhibitors in a 3 day drug treatment dose response assay. Based on t...

ORGANISM(S): Homo sapiens

2015-08-26 | E-GEOD-45558 | biostudies-arrayexpress

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

Not available

S-EPMC4878048 | biostudies-literature

Activated CD4⁺ T cells and CD14^hiCD16⁺ monocytes correlate with antibody response following influenza virus infection in humans.

Not available

S-EPMC8080109 | biostudies-literature

Simvastatin in Critically Ill Patients with Covid-19.

Not available

S-EPMC10755839 | biostudies-literature

Identifying heterogeneity of treatment effect for antibiotic duration in bloodstream infection: an exploratory post-hoc analysis of the BALANCE randomised clinical trial.